Pexidartinib for advanced tenosynovial giant cell tumor (TGCT): Long-term efficacy and safety from the phase 3 ENLIVEN and phase 1 PLX108-01 (TGCT cohort) studies Meeting Abstract

  

Authors:	Gelderblom, H.; Tap, W. D.; Palmerini, E.; Stacchiotti, S.; Wainberg, Z. A.; Desai, J.; Healey, J. H.; van de Sande, M.; Bernthal, N. M.; Peterfy, C.; Shuster, D. E.; Wang, Q.; Hsu, H.; Wagner, A. J.
Abstract Title:	Pexidartinib for advanced tenosynovial giant cell tumor (TGCT): Long-term efficacy and safety from the phase 3 ENLIVEN and phase 1 PLX108-01 (TGCT cohort) studies
Meeting Title:	55th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	37
Issue:	15 Suppl.
Meeting Dates:	2019 May 31-Jun 4
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2019-05-20
Start Page:	572s
Language:	English
ACCESSION:	WOS:000487345804138
PROVIDER:	wos
DOI:	10.1200/JCO.2019.37.15_suppl.11042
Notes:	Meeting Abstract: 11042 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/156284